Literature DB >> 6344898

Effect of cyclosporin A on the anti-leukaemia action associated with graft-versus-host disease.

S Denham, S Attridge, R K Barfoot, P Alexander.   

Abstract

Graft-versus-host disease (GVHD) was induced in Hooded (Rt1c) strain rats by means of high dose total body irradiation (TBI) and subsequent reconstitution with allogeneic bone marrow and spleen cells from WAG (Rt1u) strain donors. Untreated recipients of allogeneic cells died within 20 days of engraftment, whereas those treated daily with Cyclosporin A (CyA), given either from the day receipt of the graft (Day 0) or from Day 4, survived until the end of the experiment (Day 50). If delayed until Day 7, CyA prophylaxis was totally ineffective. Hooded rats bearing a syngeneic leukaemia were irradiated and reconstituted with allogeneic bone marrow. During the course of the ensuing graft-versus-host response (GVHR) leukaemia cells were eradicated from the spleens of the host animals. However, as a consequence of CyA prophylaxis, whether started on Day 0 or delayed until Day 4, the anti-leukaemia potential of the bone marrow allograft was completely abrogated. Anti-tumour activity after engraftment was detectable first at Day 7, i.e. the time at which the GVHR became intractable to the effects of CyA. The results indicate (1) that CyA suppresses the initial events but not the effector phase of the GVHR, and (2) that the anti-host and anti-tumour action of the GVHR may be temporally inseparable.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344898      PMCID: PMC2011364          DOI: 10.1038/bjc.1983.132

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  Use of cyclosporin A in allogeneic bone marrow transplantation in the rat.

Authors:  P J Tutschka; W E Beschorner; A C Allison; W H Burns; G W Santos
Journal:  Nature       Date:  1979-07-12       Impact factor: 49.962

3.  Reversible suppression of allo-antibody production by cyclosporin A.

Authors:  S Denham; J M Styles; R K Barfoot; C J Dean
Journal:  Int Arch Allergy Appl Immunol       Date:  1980

4.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

5.  Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytes.

Authors:  T Horsburgh; P Wood; L Brent
Journal:  Nature       Date:  1980-08-07       Impact factor: 49.962

6.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

7.  Early cellular events in a systemic graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor lymphocytes which respond to each Ag-B-determined antigenic complex.

Authors:  W L Ford; S J Simmonds; R C Atkins
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

8.  The growth patterns of two transplantable acute leukaemias of spontaneous origin in rats.

Authors:  A B Wrathmell
Journal:  Br J Cancer       Date:  1976-02       Impact factor: 7.640

  8 in total
  2 in total

1.  FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats.

Authors:  P M Markus; X Cai; W Ming; A J Demetris; J J Fung; T E Starzl
Journal:  Surgery       Date:  1991-08       Impact factor: 3.982

2.  Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics.

Authors:  Jesper R Nilsson; Tom Baladi; Audrey Gallud; Dženita Baždarević; Malin Lemurell; Elin K Esbjörner; L Marcus Wilhelmsson; Anders Dahlén
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.